As the first meta-analysis based on the sample from blood and urine, the results of present study indicated that cfDNA owned a promising role to be an ideal biomarker for the early PCa diagnosis, especially as the adjuvant tool of the PSA screening due to its outstanding specificity. Here, KLK3 is linked to posterior cortical atrophy.